Vlad  Coric net worth and biography

Vlad Coric Biography and Net Worth

CEO of Biohaven

As CEO of Biohaven, I am proud to lead a modern pharmaceutical company that is so deeply dedicated to alleviating the burden of human disease and improving lives. Our commitment to patients means so much to us, inspiring us to be audacious with our goals and driving us to be agile and inventive in fulfilling our mission. Our team proudly challenges the status quo – mindful that real medical change comes from disruptive, transformative progress; not short-term, incremental gains. We aspire to win with science, which means we resiliently follow the path of scientific innovation to uncover and advance life-changing treatment for neurological and neuropsychiatric diseases, including rare disorders.

We know the important work we do comes with great responsibility – not just to the patients that count on us, but to the investors who are instrumental to our success. While we are pleased with our track record in developing therapies that have changed millions of patients’ lives and created robust shareholder value, we know that new and different challenges lie ahead. Our team is poised and ready to draw upon our accomplishments and maximize the potential of our unique business model to continue our growth trajectory.

At Biohaven, we think and act differently! My optimism for what we can achieve is truly boundless. The potential of our science and medicine, paired with our deep compassion for patients and fearlessness in the face of adversity, is unmatched. I like to call it the “Biohaven Way” of doing business, but really it is the result of every member of our team, who day in and day out make our bold mission possible.

What is Vlad Coric's net worth?

The estimated net worth of Vlad Coric is at least $58.61 million as of April 22nd, 2024. Dr. Coric owns 1,788,417 shares of Biohaven stock worth more than $58,606,425 as of June 19th. This net worth estimate does not reflect any other assets that Dr. Coric may own. Additionally, Dr. Coric receives a salary of $1,960,000.00 as CEO at Biohaven. Learn More about Vlad Coric's net worth.

How old is Vlad Coric?

Dr. Coric is currently 53 years old. There are 5 older executives and no younger executives at Biohaven. Learn More on Vlad Coric's age.

What is Vlad Coric's salary?

As the CEO of Biohaven Ltd., Dr. Coric earns $1,960,000.00 per year. Learn More on Vlad Coric's salary.

How do I contact Vlad Coric?

The corporate mailing address for Dr. Coric and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on Vlad Coric's contact information.

Has Vlad Coric been buying or selling shares of Biohaven?

Within the last three months, Vlad Coric has bought $4,999,991.00 of Biohaven stock. Most recently, on Monday, April 22nd, Vlad Coric bought 121,951 shares of Biohaven stock. The stock was acquired at an average cost of $41.00 per share, with a total value of $4,999,991.00. Following the completion of the transaction, the chief executive officer now directly owns 1,788,417 shares of the company's stock, valued at $73,325,097. Learn More on Vlad Coric's trading history.

Who are Biohaven's active insiders?

Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.

Are insiders buying or selling shares of Biohaven?

In the last twelve months, Biohaven insiders bought shares 10 times. They purchased a total of 556,915 shares worth more than $16,299,901.23. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on May, 30th when Director John W Childs bought 28,000 shares worth more than $996,240.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.

Information on this page was last updated on 5/30/2024.

Vlad Coric Insider Trading History at Biohaven

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/22/2024Buy121,951$41.00$4,999,991.001,788,417View SEC Filing Icon  
10/5/2023Buy113,637$22.00$2,500,014.001,657,031View SEC Filing Icon  
10/31/2022Buy25,800$15.97$412,026.001,543,394View SEC Filing Icon  
10/28/2022Buy41,930$14.87$623,499.101,517,594View SEC Filing Icon  
10/25/2022Buy853,380$10.50$8,960,490.001,475,664View SEC Filing Icon  
6/26/2019Buy5,000$40.22$201,100.00View SEC Filing Icon  
3/14/2019Sell100,000$50.09$5,009,000.00View SEC Filing Icon  
3/12/2019Sell51,962$50.15$2,605,894.30View SEC Filing Icon  
6/1/2018Sell50,000$35.02$1,751,000.00View SEC Filing Icon  
5/30/2018Sell1,541$35.00$53,935.00View SEC Filing Icon  
11/1/2017Sell150,000$29.41$4,411,500.00View SEC Filing Icon  
See Full Table

Vlad Coric Buying and Selling Activity at Biohaven

This chart shows Vlad Coric's buying and selling at Biohaven by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biohaven Company Overview

Biohaven logo
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $32.77
Low: $32.76
High: $34.24

50 Day Range

MA: $38.10
Low: $32.77
High: $53.55

2 Week Range

Now: $32.77
Low: $16.45
High: $62.21


830,296 shs

Average Volume

1,344,705 shs

Market Capitalization

$2.89 billion

P/E Ratio


Dividend Yield